Phase IIa clinical study of [18F]fluciclovine: efficacy and safety of a new PET tracer for brain tumors

Akihide Kondo; Hisato Ishii; Shigeki Aoki; Masaru Suzuki; Hidekazu Nagasawa; Kazuo Kubota; Ryogo Minamimoto; Atsushi Arakawa; Masato Tominaga; Hajime Arai

doi:https://doi.org/10.1007/s12149-016-1102-y

doi.org/10.1007/s12149-016-1102-y

Phase IIa clinical study of [18F]fluciclovine: efficacy and safety of a new PET tracer for brain tumors

,

,

..., Hajime Arai

34

Annals of Nuclear Medicine2.60

Volume: 30, Issue: 9, Pages: 608 - 618

Published: Jul 14, 2016

Abstract

[18F]Fluciclovine (anti-[18F]FACBC) has demonstrated diagnostic efficacy for cancers of the brain where [18F]fludeoxyglucose has limitations. We conducted a phase IIa study of anti-[18F]FACBC to assess its accumulation pattern and safety in patients with malignant glioma. Five patients with glioma scheduled for brain tumor resection received anti-[18F]FACBC. Brain positron emission tomography (PET) was performed following intravenous...

Paper Fields

Paper Details

Title

Phase IIa clinical study of [18F]fluciclovine: efficacy and safety of a new PET tracer for brain tumors

DOI

doi.org/10.1007/s12149-016-1102-y

Published Date

Jul 14, 2016

Journal

Annals of Nuclear Medicine

Volume

30

Issue

9

Pages

608 - 618

Citation AnalysisPro

You’ll need to upgrade your plan to Pro

Looking to understand the true influence of a researcher’s work across journals & affiliations?

Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.

Learn more

Notes

History